@article{article_1694300, title={Exploring nano curcumin as a potential therapeutic alternative for glioblastoma multiforme via downregulation of growth factors and induction of apoptosis}, journal={Journal of Research in Pharmacy}, volume={29}, pages={1145–1153}, year={2025}, DOI={10.12991/jrespharm.1694300}, author={Widowati, Wahyu and Faried, Ahmad and Diki, Diki and Rahmat, Deni and Sutendi, Annisa Firdaus and Kusuma, Hanna Sari Widya and Dewi, Nindia Salsabila Mia and Zahiroh, Fadhilah Haifa and Priyandoko, Didik and Surakusumah, Wahyu and et al.}, keywords={Apoptosis, glioblastoma multiforme, growth factor, nano-curcumin, temozolomide}, abstract={Glioma is a type of brain tumor that start from neuroglial stem cells. Despite advancements in surgery and additional adjuvant therapy such as Temozolomide (TMZ), treating this tumor continues to present a challenge with notable side effects, such as toxicity and resistance to treatment. Therefore, the investigation of natural remedies becomes intriguing. This study examines the potential of nano-particle-formulated curcumin, a compound derived from Curcuma longa L as a promising antitumor agent. The research was carried out in vitro by treating Glioblastoma multiforme (GBM) cell with various concentrations (25, 50, and 100 μg/mL) of nano-particle of curcumin (NC) and TMZ 300 μM. qRT-PCR was employed to assess the relative expression of mRNA Caspase 3 (Casp-3), Insulin-like Growth Factor Binding Protein 2 (IGFBP-2), Epidermal Growth Factor Receptor (EGFR), and Extracellular Signal-Regulated Kinases (ERK). While the proportion of live, necrotic and apoptotic cells was employed utilizing flow cytometry. GBM shows a high expression of growth factors and a low expression of apoptotic gene. The treatment using NC reduced the expression of IGFBP-2, EGFR, and ERK genes, while increasing Casp-3. GBM cells shows higher apoptotic activities and lower necrotic activities after the addition of NC. In comparison to TMZ, NC demonstrates a promise as an anti-tumor agent, particularly for brain tumors, with the optimal dosage identified to be 25 μg/mL.}, number={3}, publisher={Marmara University}